The biggest advances in the management of childhood acute myeloid leukemia come from matching treatment intensity to each child’s leukemia genetics, adding targeted drugs such as FLT3 inhibitors and gemtuzumab ozogamicin, measuring leftover disease with sensitive minimal residual disease (MRD) tests, and keeping children safer through modern supportive care. Chemotherapy is still the backbone, but how much of it a child receives, and whether a transplant is needed, is now decided far more precisely than it once was.
Below I walk through how childhood acute myeloid leukemia is diagnosed and treated today, and where the field is heading. It is written for parents and caregivers first, with enough detail to be useful to students and trainees.
What Childhood AML Is and Why It Is Treated Differently
Acute myeloid leukemia (AML) is a cancer of the myeloid cells in the bone marrow, the cells that normally mature into red cells, platelets, and infection-fighting granulocytes and monocytes. In AML, immature cells called blasts multiply rapidly and crowd out normal blood production.
In children, AML accounts for roughly 15 to 20 percent of leukemias; most childhood leukemia is acute lymphoblastic leukemia instead. Because AML is less common, much of what we know comes from large cooperative groups such as the Children’s Oncology Group, which pool patients across many hospitals so that questions can be answered reliably.
Children are not simply small adults. Their leukemias carry a different mix of genetic changes, they tolerate intensive chemotherapy better than older adults, and they have decades of life ahead, so long-term side effects on the heart, fertility, and growth weigh heavily in treatment choices.
Known risk factors
Most children with AML have no identifiable cause. Some inherited conditions raise the risk, including Down syndrome, Fanconi anemia, neurofibromatosis type 1, and other inherited bone marrow failure syndromes. Prior chemotherapy or radiation for another cancer is also a recognized risk factor.
How Diagnosis Now Drives Treatment
A child with AML may present with tiredness, pallor, fever, repeated infections, easy bruising, nosebleeds, or bone pain. These symptoms reflect the loss of normal blood cells rather than anything specific to AML, so the diagnosis rests on laboratory testing.
Workup starts with a complete blood count and blood smear, followed by a bone marrow aspirate and biopsy. Flow cytometry (immunophenotyping) confirms the cells are myeloid, while cytogenetic and molecular tests look for chromosome rearrangements and gene mutations. A lumbar puncture checks whether leukemia has reached the fluid around the brain and spinal cord.
The genetic results are where modern management really begins. They sort children into risk groups that decide how intensive treatment should be.
| Risk group | Typical genetic findings | General approach |
|---|---|---|
| Lower risk | t(8;21), inv(16), NPM1 mutation, certain CEBPA mutations | Chemotherapy alone; transplant usually reserved for relapse |
| Higher risk | Monosomy 7, FLT3-ITD with a high allelic ratio, certain KMT2A rearrangements, poor MRD response | Intensive chemotherapy, often targeted therapy, and stem cell transplant in first remission |
| Special subtype: APL | t(15;17), PML-RARA | All-trans retinoic acid (ATRA) plus arsenic trioxide, with little or no conventional chemotherapy |
| Special subtype: Down syndrome | GATA1 mutation (myeloid leukemia of Down syndrome) | Reduced-intensity chemotherapy, because these children respond very well and are more sensitive to toxicity |
Chemotherapy: The Foundation, Refined
Standard treatment is given in phases. Induction aims to clear leukemia from the marrow and achieve complete remission. It is built around cytarabine and an anthracycline such as daunorubicin, frequently with etoposide. Most regimens use two induction courses.
Intensification (consolidation) follows with further courses, often including high-dose cytarabine, to eliminate cells that survived induction. Unlike childhood ALL, pediatric AML does not use a long maintenance phase; the whole program is shorter but more intense, usually lasting several months, much of it in hospital.
The refinement has been in dosing and selection rather than in brand-new chemotherapy drugs. Anthracyclines damage the heart in a dose-dependent way, so protocols now cap total exposure, monitor heart function with echocardiograms, and may add a cardioprotective agent such as dexrazoxane.
Targeted Therapy and Immunotherapy
Several newer agents now join chemotherapy for selected children. For broader context on these drugs across age groups, see our overview of myeloid leukemia treatment strategies.
- Gemtuzumab ozogamicin is an antibody that binds CD33, a protein on the surface of most AML blasts, and delivers a toxin directly to them. It is added to induction for many children.
- FLT3 inhibitors block a signaling protein that is overactive in FLT3-ITD positive AML. Drugs in this class, such as midostaurin and gilteritinib, are being combined with chemotherapy in children with these mutations.
- Menin inhibitors are a newer class aimed at leukemias with KMT2A rearrangements or NPM1 mutations, currently studied mainly in relapsed disease.
- Cellular immunotherapy, including CAR T-cell approaches that have transformed relapsed ALL, is under investigation in AML. Finding a target present on leukemia cells but absent from healthy blood stem cells remains the main hurdle.
MRD Testing and Stem Cell Transplant
Minimal residual disease is leukemia too scarce to see under the microscope but detectable by flow cytometry or molecular methods. Children who still have measurable MRD after the first course of induction are at higher risk of relapse, so MRD response has become one of the most important factors in deciding the next step.
Allogeneic hematopoietic stem cell transplantation replaces the child’s marrow with donor stem cells, and the donor immune system helps suppress any remaining leukemia. Because transplant carries real risks, including graft-versus-host disease and infection, modern protocols reserve it in first remission for high-risk genetics or poor MRD response, and spare lower-risk children from it.
Supportive Care and Long-Term Follow-Up
Some of the most important progress has come from keeping children safe during treatment. Intensive AML therapy causes long periods of very low neutrophil counts, and infection has historically been a leading cause of treatment-related death.
Current practice includes preventive antibiotics and antifungals during these periods, prompt treatment of fever, transfusion support, and careful nutrition. After treatment ends, survivors need long-term follow-up for heart function, growth, fertility, hearing, and learning, because late effects can appear years later. You can read more about survivorship in our article on pediatric leukemia.
Key Takeaways
- Genetic testing at diagnosis now determines how intensive treatment should be.
- Cytarabine plus an anthracycline remains the backbone, with better heart protection than in the past.
- Gemtuzumab ozogamicin and FLT3 inhibitors are added for children whose leukemia carries the right targets.
- MRD testing helps decide who needs a stem cell transplant in first remission.
- Supportive care and survivorship clinics are as much a part of modern management as the drugs themselves.
If you are comparing AML with the more common childhood leukemia, our guide to pediatric acute lymphoblastic leukemia explains the differences, and our article on navigating leukemia from diagnosis to advanced treatment covers the wider journey. The leukemia guide brings all of these topics together.
Frequently Asked Questions
Is childhood AML curable?
Yes, many children with AML are cured, and outcomes have improved steadily over recent decades. The likelihood depends heavily on the leukemia’s genetic features and how quickly it responds to the first course of treatment. Your child’s oncology team can explain what their specific results mean.
How long does treatment for childhood AML take?
Chemotherapy usually runs for several months, delivered in four or five courses with recovery periods between them. Much of this time is spent in hospital or close to it because of infection risk. Children who need a transplant have a longer overall course.
Does every child with AML need a bone marrow transplant?
No. Children with lower-risk genetic features who respond well to induction are usually treated with chemotherapy alone. Transplant in first remission is generally reserved for high-risk disease or persistent MRD.
Should my child join a clinical trial?
Most children with AML in countries with cooperative pediatric oncology groups are treated on or according to clinical trial protocols. Trials are how new approaches, such as targeted drugs and refined risk groups, become standard care. Ask the team what trials are open and how they differ from standard treatment.
What late effects should we watch for after treatment?
The most important are effects on heart function from anthracyclines, along with growth, hormone, fertility, and learning issues. Survivors should have scheduled long-term follow-up, including periodic heart checks. Report new breathlessness, reduced exercise tolerance, or school difficulties to the survivorship team.
